Stocks of the Hour: Findi, Immutep, ImpediMed
Stocks of the Hour: Findi, Immutep, ImpediMed
To register for today's webinar click here.
要注册今天的网络研讨会，请单击此处。
Findi (ASX:FND) has extended the existing State Bank of India contract until 30 September 2024. Commenting on the SBI contract extension, Findi Chairman Mr Nicholas Smedley said: "The SBI contract extension combined with the improved terms of the new SBI contact announced on 30 October will enable Findi to deliver significant organic growth over coming years. Shares are trading 10 per cent higher at 77 cents.
Findi (ASX: FND) 已将印度国家银行的现有合同延长至2024年9月30日。Findi董事长尼古拉斯·斯梅德利在评论SBI合同延期时说：“SBI合同的延期，加上10月30日宣布的SBI新合同条款的改进，将使Findi能够在未来几年实现显著的有机增长。股价上涨10％，至77美分。
Immutep (ASX:IMM) has announced new biomarker data from the TACTI-002 Phase II trial evaluating efti. The data shows statistically significant increases of Th1 biomarkers, circulating immune cells, and RNA levels of immune activating genes were observed and linked to improved clinical outcomes. Shares are trading 5 per cent higher 31.5 cents.
Immutep (ASX: IMM) 公布了评估efti的 TACTI-002 II期试验的新生物标志物数据。数据显示，观察到Th1生物标志物、循环免疫细胞和免疫激活基因的RNA水平在统计学上显著增加，这与临床结果的改善有关。股价上涨5％，上涨31.5美分。
ImpediMed (ASX:IPD) announced that UnitedHealthcare, the largest US private payor updates the medical policy for BIS. In response, Rick Valencia, Managing Director and CEO of ImpediMed, stated, "this is a very exciting step for patients at risk of lymphoedema. We expect this change to mean that we will have silent coverage from UnitedHealthcare, when the policy goes into effect in January 2024. With this change, UnitedHealthcare will be the second Top 5 national payor to cover SOZO testing for lymphoedema. Cigna was the first." Shares are trading 8.7 per cent higher at 12.5 cents.
ImpediMed（澳大利亚证券交易所股票代码：IPD）宣布，美国最大的私人支付机构UnitedHealthcare更新了BIS的医疗政策。对此，ImpediMed董事总经理兼首席执行官里克·瓦伦西亚表示：“对于有淋巴水肿风险的患者来说，这是非常激动人心的一步。我们预计，这一变化将意味着，当该政策于2024年1月生效时，我们将获得UnitedHealthcare的无声保险。有了这一变化，UnitedHealthcare将成为第二家承保SOZO淋巴水肿检测的全国前五名支付机构。信诺是第一个。”股价上涨8.7％，至12.5美分。
